Adnexal tumors

Displaying 5 studies

  • Rare Cutaneous Tumors and Unresolved Issues with the Current AJCC Cutaneous Carcinoma Staging System Rochester, MN

    Our aim is to study non-melanoma skin cancers (NMSC), rare and adnexal tumor outcomes in the context of the current cutaneous AJCC staging system.  We will also examine these rare tumors for other potentially significant factors.

  • A Study to Evaluate Regulation of the Metabolism of T-Cells by the Tumor Microenvironment in Ovarian Cancer Metastasis Scottsdale/Phoenix, AZ

    The purpose of this study is to analyze how the immune cell repertoire changes during early and late metastasis which could shed light into how the tumor microenvironment in metastatic disease becomes tumor permissive.

  • A Study to Evaluate the Venn Ovarian CAncer Liquid Biopsy Jacksonville, FL

    The primary purpode of this study is to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the InterVenn Ovarian Cancer Liquid Biopsy among women with ovarian adnexal mass for which a surgery is planned.

  • Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL

    This phase II trial is studying giving veliparib together with carboplatin to see how well they work compared to veliparib alone in treating patients with stage III or stage IV breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether veliparib is more effective with or without carboplatin in treating breast cancer.

  • Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Rochester, MN; Jacksonville, FL; Scottsdale/Phoenix, AZ

    This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may ...


Mayo Clinic Footer